Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2025 | BETAMI-DANBLOCK: Randomized Discontinuation of Beta-Blockers after MI

The routine use of beta-blockers after acute myocardial infarction (AMI) has been a historical recommendation based on...
Dr. Omar Tupayachi -
Learn More
Coronary disease

ESC 2025 | DIGIT-HF: Digitoxin in Heart Failure with Reduced Ejection Fraction

Heart failure with reduced ejection fraction (HFrEF) continues to represent a clinical challenge despite advances in pharmacological...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

ESC 2025 | What Should We Do With Beta-Blockers Post-MI in Patients With Preserved LVEF?

The evidence supporting the use of beta-blockers after myocardial infarction (MI) is strong in patients with ventricular...
Dr. Juan Manuel Pérez -
Learn More
Acute coronary syndromes

ESC 2025 | DUAL-ACS: Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes

The DUAL-ACS trial, a randomized multicenter study, was designed to evaluate whether a strategy of P2Y12 inhibitor...
Dr. Juan Manuel Pérez -
Learn More
Peripheral vascular disease

ESC 2025 | SWEDEPAD 1 and 2: Paclitaxel-Coated Devices in Peripheral Artery Disease

In patients with peripheral artery disease, “improving” prognosis means relieving walking pain, increasing walking distance, preventing amputations,...
Dr. Juan Manuel Pérez -
Learn More
Pharmacology

Can Colchicine Reduce Post-TAVR Conduction Disturbances?

Courtesy of Dr. Juan Manuel Pérez. Partly caused by perioperative inflammation, conduction disturbances often follow TAVR. Colchicine, known...
Dr. Juan Manuel Pérez -
Learn More
Antithrombotic Anticoagulants

8 Questions About Left Atrial Appendage Closure: Contributions from the 2025 SCAI/HRS Review

Courtesy of Dr. Juan Manuel Pérez. Percutaneous left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation...
Dr. Juan Manuel Pérez -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Tricuspid Regurgitation, TriBicaval Registry

Dr. Carlos Fava - 0
Tricuspid regurgitation (TR) is a condition whose prevalence is expected to increase in the coming years. Surgery presents important challenges and is associated with...

IVI-Guided PCI vs Coronary Artery Bypass Surgery in Left Main Coronary or Multivessel Disease

Dr. Andrés Rodríguez - 0
Several randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with left main...

Edge-To-Edge Treatment with PASCAL: Are There Sex-Specific Differences?

Dr. Carlos Fava - 0
Mitral regurgitation (MR) is a common valve disease associated with heart failure, hospitalizations, and mortality.  In women, it is often overlooked and some analyses have...

Institutional News

Watch again – New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology

solaci - 0
You can now watch our webinar on “New Guidelines for the Management of Heart Valve Disease: Implications for Interventional Cardiology”, held via Zoom on...

ESC 2025: Results of the NEO-MINDSET study — exclusive presentation and analysis with Dr. Pedro Lemos

solaci - 0
Following the presentation of the NEO-MINDSET study in the Late Breaking Clinical Trials sessions at the European Society of Cardiology Congress (ESC 2025), Dr....

SOLACI Webinar – New Guidelines for the Management of Valvular Heart Disease: Implications for Interventional Cardiology

solaci - 0
A new SOLACI virtual scientific event is coming up as part of the scientific coverage of the ESC 2025 Congress. This session will focus on...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy